Serious adverse events · people with hepatic encephalopathy
1 finding from 1 review
Serious adverse events · people with hepatorenal syndrome
Terlipressin showed no clear difference in serious adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower serious adverse events compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · people with hepatorenal syndrome
Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events · people with chronic liver diseases
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Serious adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · hospitalised adults at nutritional risk
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether non‐absorbable disaccharides changes non‐serious adverse events (secondary outcome) compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Serious adverse eventsc ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in serious adverse eventsc ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Non‐serious adverse events · farmworkers, soldiers, and people in endemic areas
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events · people with chronic liver diseases
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events · patients with covert or overt hepatic encephalopathy
It is very uncertain whether acetyl‐L‐carnitine changes non‐serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review